Opendata, web and dolomites

HifLICs SIGNED

Acute Myeloid Leukemia Leukemic Initiating Cells: Contribution of hypoxia/HIF pathway to chemoresistance and relapse

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HifLICs project word cloud

Explore the words cloud of the HifLICs project. It provides you a very rough idea of what is the project "HifLICs" about.

me    pointing    hif    drugs    solid    suggested    lics    pathogenesis    inducible    suppressor    resistant    heterogeneity    techniques    benefit    resistance    technologies    patient    hypoxic    quite    driving    substantial    single    thought    heterogeneous    regulators    supporting    hifs    classified    tumors    progenitor    scientific    date    subgroup    lic    alterations    practical    transcriptional    regulated    transcription    mediates    independent    vs    tumor    cell    clinical    disease    genotoxic    initiating    survive    treatment    empowering    cellular    localization    inactive    therapies    metabolically    cytotoxic    bone    barrier    dormancy    myeloid    human    relapse    hypoxia    action    molecular    hematopoietic    types    aml    investigator    complementary    susceptible    niche    broad    stage    family    controversial    group    candidate    extend    oncogenic    acquired    near    therapeutic    acute    samples    therapy    marrow    genetic    diagnosis    chemotherapy    cytogenetic    genes    cells    criteria    leukemia    caused    dormant    diseases    constitutes   

Project "HifLICs" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS 

Organization address
address: CARRER MUNTANER 383 3/2
city: BARCELONA
postcode: 8021
website: www.carrerasresearch.org

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 158˙121 €
 EC max contribution 158˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS ES (BARCELONA) coordinator 158˙121.00

Map

 Project objective

Acute myeloid leukemia (AML) is a heterogeneous group of diseases caused by acquired cytogenetic and molecular alterations in hematopoietic progenitor cells. There is a substantial need to develop new therapeutic approaches to AML; however, the genetic heterogeneity of AML constitutes a barrier for the development of targeted therapies. Leukemia relapse after treatment is most often caused by a subgroup of cells commonly referred to as leukemia initiating cells (LICs), which are resistant to chemotherapy. It is thought that this resistance is the result of several properties unique to LICs, including their dormant and metabolically inactive state, making them less susceptible to genotoxic drugs. The localization of the LICs in the hypoxic bone marrow niche has been proposed as a driving factor for dormancy. The HIF (hypoxia-inducible factor) family of transcription factors mediates cellular adaptation to hypoxia. While the role of HIFs in the pathogenesis of solid tumors is quite well established, they have only recently been suggested as key regulators of LICs in specific types of leukemia. Yet, results to date are highly controversial, with some studies supporting an oncogenic activity for HIFs and others pointing to a tumor suppressor role.

We propose a broad transcriptional study of human AML classified by cytogenetic criteria and disease stage (diagnosis vs relapse). We will focus on HIF-regulated target genes in the LIC subgroup and evaluate LIC heterogeneity using state-of-the-art single-cell technologies. Our results should extend our understanding of the ability of LICs to survive cytotoxic therapy and help to identify candidate targets for clinical application.

The use of AML patient samples and single-cell techniques included in this proposal will increase my scientific knowledge and practical experience. I will also benefit from the complementary planned activities of the action, empowering me to become an independent investigator in the near future.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HIFLICS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HIFLICS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NPsVLCD (2019)

Natural Product-Inspired Therapies for Leishmaniasis and Chagas Disease

Read More  

iRhomADAM (2020)

Uncovering the role of the iRhom2-ADAM17 interaction in inflammatory signalling

Read More  

NeuroSens (2019)

Neuromodulation of Sensory Processing

Read More